Does Cigna Cover GLP-1 Medications? (2026)
Coverage rules, copays, prior auth requirements, and appeal options for Cigna members seeking Wegovy, Ozempic, Zepbound, or Mounjaro.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Coverage by Medication[8]
| Medication | Cigna Coverage |
|---|---|
| Wegovy (semaglutide) | Cigna covers Wegovy on many commercial plans with prior authorization (IP0206 §III, effective 04/30/2026). Adult initial approval is 8 months if patient is >=18, has engaged in >=3 months of behavioral modification and dietary restriction, has BMI >=30 OR BMI >=27 with one of 11 weight-related comorbidities (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, COPD, MASLD/NAFLD, polycystic ovarian syndrome, or coronary artery disease), and uses Wegovy concomitantly with a reduced-calorie diet. Continuation/reauthorization is 1 year and requires documented >=5% baseline body-weight loss. Pediatric (>=12 to <18) initial 8-month approval requires BMI >=95th percentile + 3-month behavioral/diet trial; continuation requires >=1% BMI reduction. A separate MACE risk-reduction pathway (1-year approval) covers patients >=18 with BMI >=27 and established cardiovascular disease — no weight-loss requirement. |
| Ozempic (semaglutide) | Covered for type 2 diabetes per CNF 360 (last selected revision 01/07/2026). Step therapy gate (verbatim): if criteria for previous use of an oral diabetes medication in the past 130 days are not met, OR patient is <18, coverage requires prior authorization. CRITICAL: single-entity metformin and Rybelsus do NOT satisfy the 130-day step. PA approval is 1 year if patient is >=18. |
| Zepbound (tirzepatide) | Covered per IP0206 §V (effective 04/30/2026) with the same 4-prong adult initial criteria as Wegovy: >=18, 3-month behavioral/diet trial, BMI >=30 OR BMI >=27 with one of the 11 comorbidities, concomitant lifestyle. Initial approval is 8 months; continuation is 1 year and requires >=5% baseline body-weight loss. Separate moderate-to-severe OSA-in-obesity pathway (1-year initial) requires AHI >=15 by sleep study, BMI >=30, and no central sleep apnea / Cheyne-Stokes; OSA continuation requires >=10% body-weight loss after >=1 year plus prescriber-attested OSA stability. Quantity limits per CNF 840 (current): 4 pens or vials per 28 days at retail; 12 per 84 days at home delivery — no overrides across all strengths. |
| Mounjaro (tirzepatide) | Covered for type 2 diabetes per CNF 360 (last selected revision 01/07/2026). Step therapy gate (verbatim): if criteria for previous use of an oral diabetes medication in the past 130 days are not met, OR patient is <10 years of age, coverage requires prior authorization. CRITICAL: single-entity metformin and Rybelsus do NOT satisfy the step — a different oral antidiabetic must be in the lookback. PA approval is 1 year if patient is >=10 years of age. (Mounjaro minimum age was lowered from >=18 to >=10 effective 01/07/2026 per the policy History note.) |
| Foundayo (orforglipron) | Covered per IP0206 §II (effective 04/30/2026). Same 4-prong adult initial framework as Wegovy/Zepbound: >=18, 3-month behavioral/diet trial, BMI >=30 OR BMI >=27 with one of the 11 weight-related comorbidities, concomitant lifestyle. Initial approval is 8 months; continuation is 1 year and requires documented >=5% baseline body-weight loss. Foundayo is NOT yet listed in the standalone CNF 684 weight-loss PA policy as of 02/25/2026; IP0206 is the canonical source. |
| Typical copay (when covered) | $25-$75 / month |
If You're Denied by Cigna
If Cigna denies coverage for Wegovy or Zepbound, you still have affordable options. Compounded semaglutide and tirzepatide are dispensed by licensed 503A pharmacies[7] and cost $149-$299/month — a fraction of brand-name pricing. Brand-name GLP-1 medications are generally an HSA/FSA-eligible medical expense with a prescription[5], and many plan administrators also accept compounded GLP-1s with a Letter of Medical Necessity. The providers below ship to all 50 states and offer same-week prescriptions.
Many large employers offer self-funded health plans governed by ERISA rather than state insurance law, which gives them discretion over whether to cover anti-obesity medications[6]. If your employer self-funds its plan, check the Summary Plan Description for the specific GLP-1 coverage language.
Before going cash-pay, file a formal appeal with Cigna. Many denials are overturned with a Letter of Medical Necessity from your prescriber documenting BMI, comorbidities, and prior failed weight-loss attempts.
For the literal text of every Cigna GLP-1 PA clause — the 11-condition comorbidity list, the 130-day step-therapy rule that excludes single-entity metformin, the Mounjaro ≥10-year-old change, the Zepbound OSA pathway, the Wegovy MACE pathway, the Foundayo (orforglipron) handling, and the CNF 840 quantity limits — see our Cigna GLP-1 Prior Authorization Guide.
Top cash-pay GLP-1 providers if Cigna won't cover it
Compounded semaglutide and tirzepatide are widely available on a cash-pay basis — often for less than a plan's copay after a denial. These are our top-ranked picks, followed by a fuller list of alternatives.
Top picks
Compare the top providers at a glance
Logos, our editorial rating, price, medications, and coverage — the fastest way to narrow the list.
- ★ Editor's Pick
mainstream telehealth GLP-1 access
From /mo$99Coverage50 statesMedicationsSemaglutideTirzepatide - Best Budget
best overall value
From /mo$99Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide lab-monitored compounded GLP-1 with mandatory video visit
From /mo$112Flat at every doseCoverage39 statesMedicationsSemaglutideTirzepatide- Nationwide Coverage
compounded GLP-1/GIP combo on a yearly plan with free shipping
From /mo$149Flat at every doseCoverage50 statesMedicationsTirzepatideSemaglutide mainstream telehealth GLP-1 access
From /mo$99Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
★ Editor's Pick mainstream telehealth GLP-1 access | $99 | SemaglutideTirzepatide | 50 states | Visit → | |
Best Budget best overall value | $99 Flat pricing | SemaglutideTirzepatide | 50 states | Visit → | |
 lab-monitored compounded GLP-1 with mandatory video visit | $112 Flat pricing | SemaglutideTirzepatide | 39 states | Visit → | |
Nationwide Coverage compounded GLP-1/GIP combo on a yearly plan with free shipping | $149 Flat pricing | TirzepatideSemaglutide | 50 states | Visit → | |
 mainstream telehealth GLP-1 access | $99 Flat pricing | SemaglutideTirzepatide | 50 states | Visit → |
More compounded alternatives
Editorial score · methodology
Aurelius Health Group
Best for: transparent, care-inclusive compounded tirzepatide microdosing
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Chronos Body Health & Wellness
Best for: physician-led GLP-1 care with brand-name and microdosing options
Editorial score · methodology
Get StartedRead full Chronos Body Health & Wellness review →Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Iron Med RX
Best for: oral or injectable compounded GLP-1, one provider, account-gated pricing
Editorial score · methodology
Kairos Aesthetic and Longevity Medicine
Best for: Irving/Dallas patients wanting in-person, physician-led weight loss care
Editorial score · methodology
Get StartedRead full Kairos Aesthetic and Longevity Medicine review →Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Sprout Health
Best for: LegitScript-verified compounded GLP-1 via named pharmacies
Editorial score · methodology
Vyvron
Best for: a locked founding rate from a platform that names its clinical partner and holds a real LegitScript seal
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Prior authorization (PA) · Insurance and regulatory
- Step therapy · Insurance and regulatory
- Off-label use · Insurance and regulatory
- Compounded GLP-1 · Pharmacy and drug forms
Cigna Coverage Updates
Get notified when Cigna GLP-1 coverage rules change.
Sources & methodology — as of August 2026
- 1.KFF — Employer Health Benefits Annual Survey— Kaiser Family Foundation.
- 2.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 3.CMS — Medicare Part D Prescription Drug Coverage Program— Centers for Medicare & Medicaid Services.
- 4.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
- 6.U.S. Department of Labor — ERISA and Employer Health Plans— U.S. Department of Labor, Employee Benefits Security Administration.
- 7.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 8.Weight Loss Rankings insurer coverage index (manually curated formulary data)— Weight Loss Rankings.